Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Barclays PLC

Barclays PLC grew its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 65.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 79,658 shares of the company’s stock after buying an additional 31,527 shares during the period. Barclays PLC owned 0.15% of Kodiak Sciences worth $208,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of KOD. LJI Wealth Management LLC increased its position in shares of Kodiak Sciences by 21.3% during the third quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock valued at $45,000 after acquiring an additional 3,000 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Kodiak Sciences by 18.5% in the second quarter. American Century Companies Inc. now owns 54,323 shares of the company’s stock valued at $128,000 after purchasing an additional 8,470 shares during the period. SG Americas Securities LLC purchased a new position in shares of Kodiak Sciences in the third quarter valued at approximately $33,000. State Street Corp boosted its stake in shares of Kodiak Sciences by 1.8% in the third quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after purchasing an additional 14,711 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in shares of Kodiak Sciences in the second quarter valued at approximately $36,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Stock Up 2.2 %

Kodiak Sciences stock opened at $9.32 on Tuesday. Kodiak Sciences Inc. has a 52 week low of $2.18 and a 52 week high of $11.60. The firm’s 50-day simple moving average is $7.20 and its 200 day simple moving average is $4.30. The firm has a market capitalization of $490.46 million, a PE ratio of -2.55 and a beta of 2.11.

Wall Street Analyst Weigh In

Several research firms have recently commented on KOD. HC Wainwright reissued a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research note on Friday, November 15th. Barclays lifted their price target on shares of Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 9th.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.